CTMX CytomX Corp Earnings per share growth in current year

Official company branding of CytomX Therapeutics (CTMX)

CytomX Therapeutics (CTMX) is integrating ESG principles into the development of targeted therapies, adhering to bioethics and environmental standards. The annual EPS growth rate reflects revenue dynamics, with the value holding at -156.30. Financial stability is supported by partner payments and adherence to testing timelines. Business development is based on reducing the toxicity of drugs for solid tumors through innovative antibodies.

cytomx.com (CTMX) Net earnings per share growth this year: for the period 07/04/2022 - 11/14/2026

Analytical breakdowns and data insights for company CytomX Therapeutics (CTMX)

- current price and projected stock value:
Quote Chart CytomX Pharma|CTMX - Price Target Chart
- market capitalization data:
Market Value CytomX Corp|CTMX - Enterprise Value
- book capitalization indicators:
Book Value per Share CytomX Therapeutics|CTMX - Company Net Assets|Market Cap to Book Value Multiple cytomx.com|CTMX - Company Total Assets
- debt burden and liquidity indicators:
Aggregate Debt to Equity CytomX Therapeutics|CTMX - Long-Term Debt to Equity|Current Liabilities to Capital cytomx.com|CTMX - Company Debts|Debt to Net Assets Ratio CytomX Corp|CTMX - Company Long-Term Debt|Company Current Liabilities CytomX Therapeutics|Interim Coverage Ratio cytomx.com
- earnings and market multiples details:
CTMX - Net Profit|Future Profit CytomX Therapeutics|CTMX - Price to Earnings Ratio|Projected Price to Earnings Ratio CytomX Corp|CTMX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio CytomX Corp|CTMX - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months CytomX Therapeutics|CTMX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months cytomx.com|CTMX - Net earnings per share growth this year|Projected earnings per share growth rate for next year CytomX Therapeutics
- company sales and revenue statistics:
CTMX - Company Sales|Company Future Revenue CytomX Pharma|CTMX - Market Cap to Revenue|Price to Expected Revenue Ratio CytomX Corp
Basic company analysis:CytomX Pharma (CTMX)
Product sample of CytomX Therapeutics Inc

For the biotechnology company CytomX Therapeutics (CTMX), which relies on grants and partnership tranches, this indicator serves as a measure of capital management efficiency in the absence of retail sales. By analyzing the YoY net income per share trend, an investor can see the percentage deviation of the current EPS from the previous year's value, allowing for an assessment of the financial foundation's stability while undergoing clinical trials.

Main competitors

Earnings per share trend in current year GERN (Geron Corp)|Earnings per share growth in current year Nanobiotix Corp|Earnings per share growth in current year BCYC|Earnings growth in current year CATX|Earnings growth in current year genelux.com (GNLX)|Molecular Partners AG - Net earnings per share growth this year|Net earnings per one share growth for the current year ONCY (Oncolytics Biotech, Inc.)|Lisata - Earnings growth in current year|Earnings per share trend in current year MBRX|galeratx.com (GRTX) - Earnings per share growth in current year|Earnings per share growth rate in current year mtem.com (MTEM)